


Wiley Series on Technologies for the Pharmaceutical Industry  
Sean Ekins, Series Editor

# Systems Biology in Drug Discovery and Development



Edited by  
*Daniel L. Young and Seth Michelson*



# **SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT**

## **Wiley Series on Technologies for the Pharmaceutical Industry**

**Sean Ekins, Series Editor**

*Computational Toxicology: Risk Assessment for Pharmaceutical and Environmental Chemicals*

Edited by Sean Ekins

*Pharmaceutical Applications of Raman Spectroscopy*

Edited by Slobodan Sasic

*Pathway Analysis for Drug Discovery: Computational Infrastructure and Applications*

Edited by Anton Yuryev

*Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools*

Edited by Sean Ekins and Jinghai J. Xu

*The Engines of Hippocrates: From the Dawn of Medicine to Medical and Pharmaceutical Informatics*

Barry Robson and O. K. Baek

*Pharmaceutical Data Mining: Approaches and Applications for Drug Discovery*

Edited by Konstantin V. Balakin

*The Agile Approach to Adaptive Research: Optimizing Efficiency in Clinical Development*

Michael J. Rosenberg

*Pharmaceutical and Biomedical Project Management in a Changing Global Environment*

Edited by Scott D. Babler

*Systems Biology in Drug Discovery and Development*

Edited by Daniel L. Young and Seth Michelson

## **Editorial Advisory Board**

Dr. Renee Arnold (ACT LLC, USA)

Dr. David D. Christ (SNC Partners LLC, USA)

Dr. Michael J. Curtis (Rayne Institute, St Thomas' Hospital, UK)

Dr. James H. Harwood (Delphi BioMedical Consultants, USA)

Dr. Maggie A.Z. Hupcey (PA Consulting, USA)

Dr. Dale Johnson (Emiliem, USA)

Prof. Tsuguchika Kaminuma (Tokyo Medical and Dental University, Japan)

Dr. Mark Murcko (Vertex, USA)

Dr. Peter W. Swaan (University of Maryland, USA)

Dr. Ana Szarfman (Food and Drug Administration, USA)

Dr. David Wild (Indiana University, USA)

---

# **SYSTEMS BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT**

---

Edited by

Daniel L. Young  
Seth Michelson



A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2012 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey  
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at [www.copyright.com](http://www.copyright.com). Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permissions>.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at [www.wiley.com](http://www.wiley.com).

***Library of Congress Cataloging-in-Publication Data:***

Systems biology in drug discovery and development / edited by Daniel L. Young, Seth, Michelson.

p. ; cm.

Includes bibliographical references.

ISBN 978-0-470-26123-1 (cloth)

1. Drug development. 2. Systems biology. I. Young, Daniel L., editor.  
II. Michelson, Seth., editor.

[DNLM: 1. Drug Discovery—methods. 2. Models, Biological. 3. Pharmacokinetics. 4. Pharmacological Processes. 5. Systems Biology—methods. QV 744]

RM301.25.S97 2011

615'19—dc22

2010043475

Printed in the United States of America

oBook ISBN: 978-1-118-01643-5

ePDF ISBN: 978-1-118-01641-1

ePub ISBN: 978-1-118-01642-8

10 9 8 7 6 5 4 3 2 1

# CONTENTS

---

|  |           |
|--|-----------|
| <b>PREFACE</b>   | <b>xi</b> |
| <b>CONTRIBUTORS</b>  | <b>xv</b> |
| <b>PART I INTRODUCTION TO SYSTEMS BIOLOGY<br/>IN APPROACH</b>  |           |
| <b>1. Introduction to Systems Biology in Drug Discovery<br/>and Development</b>                            | <b>3</b>  |
| <i>Seth Michelson and Daniel L. Young</i>  |           |
| Systems Biology in Pharmacology  | 3         |
| References   | 5         |
| <b>2. Methods for <i>In Silico</i> Biology: Model Construction and Analysis</b>                            | <b>7</b>  |
| <i>Theresa Yuraszeck, Peter Chang, Kalyan Gayen, Eric Kwei,<br/>Henry Mirsky, and Francis J. Doyle III</i> |           |
| 2.1 Introduction   | 7         |
| 2.2 Model Building   | 8         |
| 2.3 Parameter Estimation   | 21        |
| 2.4 Model Analysis   | 28        |
| 2.5 Conclusions  | 32        |
| References   | 32        |
| <b>3. Methods in <i>In Silico</i> Biology: Modeling Feedback<br/>Dynamics in Pathways</b>                  | <b>37</b> |
| <i>Peter Wellstead and Olaf Wolkenhauer</i>  |           |
| 3.1 Introduction   | 37        |
| 3.2 Statistical Modeling   | 39        |
| 3.3 Mathematical Modeling  | 46        |
| 3.4 Feedback and Feedforward   | 49        |
| 3.5 Conclusions  | 56        |
| References   | 56        |
|  | <b>v</b>  |

|  |           |
|--|-----------|
| <b>4. Simulation of Population Variability in Pharmacokinetics</b> | <b>59</b> |
| <i>Jiansong Yang</i>   |           |
| 4.1 Introduction   | 59        |
| 4.2 PBPK Modeling  | 60        |
| 4.3 Simulation of Pharmacokinetic Variability                      | 61        |
| 4.4 Conclusions and Future Directions                              | 79        |
| References   | 80        |

## PART II APPLICATIONS TO DRUG DISCOVERY

|  |            |
|--|------------|
| <b>5. Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery</b> | <b>95</b>  |
| <i>Bart S. Hendriks</i>  |            |
| 5.1 Introduction   | 95         |
| 5.2 Typical Drug Discovery Paradigm  | 97         |
| 5.3 Integrated Drug Discovery  | 99         |
| 5.4 Drivers of the Disease Phenotype: Clinical Endpoints and Hypotheses  | 100        |
| 5.5 Extracellular Disease Drivers: Mechanistic Biotherapeutic Models   | 106        |
| 5.6 Relevant Cell Models for Clinical Endpoints  | 109        |
| 5.7 Intracellular Disease Drivers: Signaling Pathway Quantification  | 110        |
| 5.8 Target Selection: Dynamic Pathway Modeling   | 117        |
| 5.9 Conclusions  | 123        |
| References   | 125        |
| <b>6. Lead Identification and Optimization</b>   | <b>135</b> |
| <i>Seth Michelson</i>  |            |
| 6.1 Introduction   | 135        |
| 6.2 The Systems Biology Tool Kit   | 139        |
| 6.3 Conclusions  | 142        |
| References   | 143        |
| <b>7. Role of Core Biological Motifs in Dose–Response Modeling: An Example with Switchlike Circuits</b>        | <b>147</b> |
| <i>Sudin Bhattacharya, Qiang Zhang, and Melvin E. Andersen</i>   |            |
| 7.1 Introduction: Systems Perspectives in Drug Discovery   | 147        |
| 7.2 Systems Biology and Toxicology   | 148        |



|     |   |     |
|-----|---|-----|
| 7.3 | Mechanistic and Computational Concepts in a Molecular or Cellular Context | 151 |
| 7.4 | Response Motifs in Cell Signaling and Their Role in Dose Response         | 152 |
| 7.5 | Discussion and Conclusions  | 165 |
|     | References  | 169 |

## **8. Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling During Discovery and Early Development** **175**

*Hans Peter Grimm, Ying Ou, Micaela Reddy, Pascale David-Pierson, and Thierry Lavé*

|      |  |     |
|------|--|-----|
| 8.1  | Introduction   | 175 |
| 8.2  | Challenges in Drug Discovery and Development   | 176 |
| 8.3  | Methodological Aspects and Concepts  | 179 |
| 8.4  | Use of PK–PD Models in Lead Optimization   | 183 |
| 8.5  | Use of PK–PD Models in Clinical Candidate Selection  | 188 |
| 8.6  | Entry-into-Human Preparation and Translational PK–PD Modeling                                | 189 |
| 8.7  | Use of PK–PD Models in Toxicology Study Design and Evaluation                                | 189 |
| 8.8  | Justification of Starting Dose, Calculation of Safety Margins, and Support of Phase I Design | 191 |
| 8.9  | Phase I and Beyond   | 193 |
| 8.10 | Support of Early Formulation Development   | 195 |
| 8.11 | Outlook and Conclusions  | 196 |
|      | References   | 197 |

## **PART III APPLICATIONS TO DRUG DEVELOPMENT**

### **9. Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases** **203**

*Zvia Agur, Naamah Bloch, Boris Gorelik, Marina Kleiman, Yuri Kogan, Yael Sagi, D. Sidransky, and Yael Ronen*

|     |   |     |
|-----|---|-----|
| 9.1 | Introduction  | 203 |
| 9.2 | Modeling Angiogenesis   | 205 |
| 9.3 | Use of Rigorous Mathematical Analysis to Gain Insight into Drug Development | 213 |
| 9.4 | Use of Angiogenesis Models in Theranostics                                  | 220 |
| 9.5 | Use of Angiogenesis Models in Drug Salvage                                  | 226 |
| 9.6 | Summary and Conclusions   | 230 |
|     | References  | 231 |

|   |            |
|---|------------|
| <b>10. Systems Modeling Applied to Candidate Biomarker Identification</b>                     | <b>239</b> |
| <i>Ananth Kadambi, Daniel L. Young, and Kapil Gadkar</i>                                      |            |
| 10.1 Introduction   | 239        |
| 10.2 Biomarker Discovery Approaches   | 245        |
| 10.3 Examples of Systems Modeling Approaches for Identification of Candidate Biomarkers       | 252        |
| 10.4 Conclusions  | 260        |
| References  | 260        |
| <b>11. Simulating Clinical Trials</b>   | <b>265</b> |
| <i>Tom Parke</i>  |            |
| 11.1 Introduction   | 265        |
| 11.2 Types of Models Used in Clinical Trial Design  | 272        |
| 11.3 Sources of Prior Information for Designing Clinical Trials                               | 276        |
| 11.4 Aspects of a Trial to Be Designed and Optimized  | 277        |
| 11.5 Trial Simulation   | 279        |
| 11.6 Optimizing Designs   | 281        |
| 11.7 Real-World Examples  | 283        |
| 11.8 Conclusions  | 284        |
| References  | 284        |
| <br><b>PART IV SYNERGIES WITH OTHER TECHNOLOGIES</b>  |            |
| <b>12. Pathway Analysis in Drug Discovery</b>   | <b>289</b> |
| <i>Anton Yuryev</i>   |            |
| 12.1 Introduction: Pathway Analysis, Dynamic Modeling, and Network Analysis                   | 289        |
| 12.2 Software Systems for Pathway Analysis  | 292        |
| 12.3 Pathway Analysis in the Modern Drug Development Pipeline                                 | 293        |
| 12.4 Conclusions  | 298        |
| References  | 299        |
| <b>13. Functional Mapping for Predicting Drug Response and Enabling Personalized Medicine</b> | <b>303</b> |
| <i>Yao Li, Wei Hou, Wei Zhao, Kwangmi Ahn, and Rongling Wu</i>                                |            |
| 13.1 Introduction   | 304        |
| 13.2 Functional Mapping   | 306        |
| 13.3 Predictive Model   | 311        |
| 13.4 Future Directions  | 315        |
| References  | 318        |

|  |            |
|--|------------|
| <b>14. Future Outlook for Systems Biology</b>  | <b>323</b> |
| <i>Daniel L. Young and Seth Michelson</i>  |            |
| 14.1 Introduction  | 323        |
| 14.2 System Complexity in Biological Systems   | 324        |
| 14.3 Models for Quantitative Integration of Data   | 325        |
| 14.4 Changing Requirements for Systems Approaches<br>During Drug Discovery and Development | 328        |
| 14.5 Better Models for Better Decisions  | 330        |
| 14.6 Advancing Personalized Medicine   | 334        |
| 14.7 Improving Clinical Trials and Enabling More<br>Complex Treatment Approaches           | 337        |
| 14.8 Collaboration and Training for Systems Biologists                                     | 340        |
| 14.9 Conclusions   | 342        |
| References   | 343        |
| <b>INDEX</b>   | <b>349</b> |



## PREFACE

---

Despite the wealth of data describing mechanisms underlying health and disease in living systems, health care costs continue to rise, and there is a growing need for improved and more affordable treatments. Efficient drug discovery and development requires methods for integrating preclinical data with patient data into a unified framework to project both efficacy and safety outcomes for new compounds and treatment approaches.

In this book we present the foundations of systems biology, a growing multidisciplinary field, applied specifically to drug discovery and development. Systems biology formally integrates knowledge and information from multiple biological sources into a coherent whole by employing proven engineering and mathematical modeling approaches. The integrated system allows rapid analysis and simulation that can inform and optimize the drug research and development processes, by formalizing, and testing, the set of acceptable hypotheses *in silico*, thereby reducing development time and costs and ultimately improving the efficacy of novel treatments.

This book is the first systems biology text to focus on how systems biology can be specifically applied to enhance drug discovery and development, with particular emphasis on real-world examples. Other texts on systems biology to date have focused on particular subdisciplines of systems biology (such as cellular networks) and have not specifically addressed drug discovery and development. This book introduces key methodologies and technical approaches for helping to solve many of the current challenges facing the pharmaceutical and biotechnology industries.

The target audience for the book includes those training or currently involved in all phases of drug discovery and development. Specific examples include life scientists, pharmacologists, computational and systems biology modelers, bioinformaticians, clinicians, and pharmaceutical/biotech management. The methods and case studies presented here will help researchers understand the diverse applications of the systems approach and integrate these technologies into their drug discovery and development programs. Those who incorporate these approaches successfully should increase their organization's competitiveness to address unmet market needs as well as more complex diseases and therapies.

The book is divided into four complementary parts. Providing a foundation for the techniques of systems biology, Part I provides an introduction to

engineering and mathematical methods employed to characterize biological systems. In particular, Chapter 2 overviews model construction and analysis, focusing on model building, parameter estimation, model validation, and sensitivity analysis. Chapter 3 presents general statistical modeling approaches as well as methods for representing and analyzing nonlinear dynamical biochemical networks, of which feedback and feedforward loops are central players. In addition to modeling fundamental biological interactions and dynamics, an essential element of the systems biology approach is the study and simulation of population-level variability. To this end, Chapter 4 presents how drug pharmacokinetics is affected by variations in drug absorption, distribution, metabolism, and excretion, illustrating methods for predicting interindividual variability essential for rationale compound evaluation.

Part II highlights systems biology techniques aimed at enhancing the drug discovery process. An essential component of drug discovery is target identification and validation. To tackle many of the challenges inherent in these processes, Chapter 5 introduces a variety of complementary systems approaches, including text-mining, disease and therapeutics modeling, large multicontext data sets, regression modeling, and network and dynamic pathway modeling. In Chapter 6, systems biology approaches are applied to lead identification and optimization disciplines. In particular, systems approaches are shown to enable building bridges between compounds' chemical and biological activities. In this way, lead identification and optimization are enhanced by the systematic quantification of the optimal pharmacokinetic and pharmacodynamic compound profiles, defined potentially for specific patient populations. Chapter 7 addresses drug safety by exploring the role of biological motifs, in particular switchlike circuits, critical for dose–response models. Such models help uncover complex emergent behaviors and reveal factors driving variable patient responses to drugs that could limit efficacy or even lead to low-incidence adverse responses. Finally, Chapter 8 presents the use of mechanistic systems models for the study of pharmacokinetics and pharmacodynamics during discovery and early development. These models integrate a mechanistic understanding of biology and disease processes into a framework to aid in the selection of lead compounds, evaluation of dosing regimens, and support of optimal study design for specific patient populations.

Part III addresses particular applications of systems biology to drug development. Illustrating practical drug development challenges, Chapter 9 details the development and validation of a multiscale mathematical model for angiogenesis, integrating molecular and tissue-level processes. Here the exemplary model is applied for treatment personalization, and results suggest that an arrested drug candidate can be efficacious if applied in combination with current standards of care. Chapter 10 presents methods for applying systems biology to candidate biomarker identification. In particular, the chapter highlights the biomarker discovery process, its application to drug development, and the utility of mechanistic systems modeling to biomarker development in cardiovascular disease and rheumatoid arthritis. Finally, to aid in the design

and execution of costly clinical programs, essential aspects of clinical trial simulations are presented in Chapter 11, where both clinical efficacy and safety are essential considerations.

In the final section of the book, Part IV, we address how systems biology technologies can synergize with other approaches. To this end, Chapter 12 presents how biological pathway analysis can be integrated into drug discovery systems approaches. Chapter 13 addresses aspects of personalized medicine and how functional mapping aimed at understanding genes and genetic networks can be used to help predict drug responses in patients. The book concludes in Chapter 14 with a broad overview of opportunities and challenges in systems biology that should ultimately help to extend both its reach and its acceptance, thereby further enhancing pharmaceutical productivity and the success of drug discovery and development for the benefit of patients.

In addition to the contributing authors of this book, we would like to thank our collaborators and colleagues throughout the years who have helped develop and apply systems biology approaches to drug discovery and development. We look forward to future advances and successes in the coming years as these approaches are applied and extended by dedicated researchers for enhanced drug discovery and development and ultimately, better care for patients.

*Palo Alto, California*

DANIEL L. YOUNG

*Redwood City, California*

SETH MICHELSON